This multi-center, multi-arm trial is evaluating the safety and efficacy of tagraxofusp, a
CD123-targeted therapy, in patients with either chronic myelomonocytic leukemia (CMML) or
myelofibrosis (MF). There are two CMML cohorts, one enrolling patients with CMML (CMML-1 or
CMML-2) who are refractory/resistant or intolerant to hypomethylating agents (HMA),
hydroxyurea (HU), or intensive chemotherapy; and one enrolling treatment-naive patients with
CMML (CMML-1 or CMML-2) with molecular features associated with poor prognosis. The MF cohort
will enroll patients who are resistant/refractory or intolerant to approved JAK therapy
(JAK1/JAK2 or JAK2).